Document Detail

Pre-eclampsia and offspring cardiovascular health: mechanistic insights from experimental studies.
Jump to Full Text
MedLine Citation:
PMID:  22455350     Owner:  NLM     Status:  MEDLINE    
Pre-eclampsia is increasingly recognized as more than an isolated disease of pregnancy. Women who have had a pregnancy complicated by pre-eclampsia have a 4-fold increased risk of later cardiovascular disease. Intriguingly, the offspring of affected pregnancies also have an increased risk of higher blood pressure and almost double the risk of stroke in later life. Experimental approaches to identify the key features of pre-eclampsia responsible for this programming of offspring cardiovascular health, or the key biological pathways modified in the offspring, have the potential to highlight novel targets for early primary prevention strategies. As pre-eclampsia occurs in 2-5% of all pregnancies, the findings are relevant to the current healthcare of up to 3 million people in the U.K. and 15 million people in the U.S.A. In the present paper, we review the current literature that concerns potential mechanisms for adverse cardiovascular programming in offspring exposed to pre-eclampsia, considering two major areas of investigation: first, experimental models that mimic features of the in utero environment characteristic of pre-eclampsia, and secondly, how, in humans, offspring cardiovascular phenotype is altered after exposure to pre-eclampsia. We compare and contrast the findings from these two bodies of work to develop insights into the likely key pathways of relevance. The present review and analysis highlights the pivotal role of long-term changes in vascular function and identifies areas of growing interest, specifically, response to hypoxia, immune modification, epigenetics and the anti-angiogenic in utero milieu.
Esther F Davis; Laura Newton; Adam J Lewandowski; Merzaka Lazdam; Brenda A Kelly; Theodosios Kyriakou; Paul Leeson
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical science (London, England : 1979)     Volume:  123     ISSN:  1470-8736     ISO Abbreviation:  Clin. Sci.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-03-29     Completed Date:  2012-05-11     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  7905731     Medline TA:  Clin Sci (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  53-72     Citation Subset:  IM    
Oxford Cardiovascular Clinical Research Facility, Department of Cardiovascular Medicine, University of Oxford, Oxford, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anoxia / complications
Cardiovascular Diseases / etiology*
Disease Susceptibility
Endothelium, Vascular / physiology
Inflammation / complications
Pre-Eclampsia / physiopathology*
Sex Characteristics
Uterus / blood supply
Vascular Endothelial Growth Factor A / physiology
Grant Support
FS/06/024//British Heart Foundation; FS/11/65/28865//British Heart Foundation
Reg. No./Substance:
0/Vascular Endothelial Growth Factor A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Clin Sci (Lond)
Journal ID (iso-abbrev): Clin. Sci
Journal ID (pmc): cls
Journal ID (publisher-id): CS
ISSN: 0143-5221
ISSN: 1470-8736
Publisher: Portland Press Ltd.
Article Information
Download PDF
© 2012 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence ( which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
Received Day: 5 Month: 12 Year: 2011
Revision Received Day: 30 Month: 1 Year: 2012
Accepted Day: 10 Month: 2 Year: 2012
Electronic publication date: Day: 23 Month: 3 Year: 2012
Print publication date: Day: 1 Month: 7 Year: 2012
Volume: 123 Issue: Pt 2
First Page: 53 Last Page: 72
ID: 3315178
PubMed Id: 22455350
Publisher Id: CS20110627
DOI: 10.1042/CS20110627

Pre-eclampsia and offspring cardiovascular health: mechanistic insights from experimental studies Title for RRH:Pre-eclampsia and offspring cardiovascular health Alternate Title:E. F. Davis and others
Esther F. Davis*
Laura Newton*
Adam J. Lewandowski*
Merzaka Lazdam*
Brenda A. Kelly
Theodosios Kyriakou
Paul Leeson*
*Oxford Cardiovascular Clinical Research Facility, Department of Cardiovascular Medicine, University of Oxford, Oxford, U.K.
†Wellcome Trust Centre for Human Genetics, Department of Cardiovascular Medicine, University of Oxford, Oxford, U.K.
‡Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, U.K.
Correspondence: Correspondence: Dr Paul Leeson (email


Traditionally pre-eclampsia was viewed as a self-limiting maternal condition that resolved completely with delivery of the placenta [1,2]. However, it is now recognized that a woman who has a pregnancy complicated by pre-eclampsia [3,4] has a 4-fold increased risk of hypertension, and a 2-fold increased risk of ischaemic heart disease and stroke [3] in the 10–15 years after the pregnancy. Intriguingly, the offspring of that pregnancy will also have increased BP (blood pressure) during childhood and nearly double the risk of stroke in later life [516]. As pre-eclampsia affects 2–5% of pregnancies, 1.2–3 million people in the U.K. and 6–15 million in the U.S.A. [1,2] are offspring of pregnancies complicated by pre-eclampsia. Experimental approaches to identify the key biological variation that infer the increased risks in this large cohort therefore have the potential to pivotally alter our understanding of the early development of cardiovascular disease and hypertension in the population. The fact that exposed children and adults can be easily identified based on precise clinical criteria, namely a diagnosis of pre-eclampsia in their mother, also raises the possibility for novel, very early, targeted, primary prevention strategies for cardiovascular risk reduction in a high risk group within the community [17].


The epidemiological data used to uncover the relationships between maternal pre-eclampsia and offspring cardiovascular health provide clues to the broad nature of the biological variation that underlies the risk [15]. Meta-analysis of available BP data indicates that children exposed to pre-eclampsia in utero have approximately 2–3 mmHg higher SBP (systolic BP) during childhood and young adult life [18]. This difference, if maintained into adulthood, would be associated with a 12% increased risk from stroke [19,20]. In reality, long-term follow-up studies demonstrate a doubling of risk [6]. The key biological pathways relevant to offspring cardiovascular health are therefore likely to have additional effects, on other features of stroke risk, beyond clinic BP measures alone.

Pre-eclampsia is a condition with a heritability of approximately 55% [21], which is contributed to by both maternal and fetal genes. It is plausible that some of the alterations in risk seen in the offspring of pre-eclamptic pregnancies relate to shared genetic factors between the mother and child. The modification to these pathways also appears to be induced specifically by in utero exposure to pre-eclampsia. Siblings of offspring born to pregnancies complicated by pre-eclampsia, who themselves were born to uncomplicated pregnancies, do not demonstrate the vascular abnormalities seen in the offspring [11]. This observation has clear parallels with the ‘developmental programming’ hypothesis [22], which holds that an insult or deprivation during a critical period of growth and development can lead to long-term alterations in the risk of chronic disease [23]. This hypothesis was developed in response to epidemiological data that associated a low birthweight, a pregnancy-related outcome with multi-factorial determinants, to a variety of cardiovascular and non-cardiovascular outcomes, including mortality from coronary artery disease [24,25], BP [24], the metabolic syndrome [26] and non-insulin-dependent diabetes (Type 2 diabetes) [27].

Offspring of pre-eclamptic pregnancies, particularly those with early-onset pre-eclampsia, can also have a low birthweight due to IUGR (intra-uterine growth restriction) or pre-term birth [23]. Prematurity and IUGR have themselves been associated with alterations in cardiovascular risk factors [28,29]. Furthermore, early- and late-onset pre-eclampsia are increasingly being recognized as different subclasses of disease, which may have different implications for cardiovascular risk in the offspring [30]. This complicated combination of in utero insults means that in many currently available human studies it is challenging to separate the effects of exposure to pre-eclampsia from other in utero insults. However, if a baby is born at term without IUGR, but their mother had pre-eclampsia, they still have an increased risk of stroke [6] and vascular abnormalities [31] that persist after adjustment for birthweight. It therefore seems plausible that there is a unique insult within the in utero environment during pre-eclampsia which is incremental to, or acts in synergy with, any risks inferred by IUGR. This hypothesis is supported further by the observation that pre-term birth largely protects offspring from the adverse associations between birthweight and later cardiovascular disease [24,32]. Pre-eclampsia is one of the leading causes of pre-term birth, and the largest differences in later BP are seen in those offspring of pre-eclamptic pregnancies born pre-term [12]; findings that focus attention on key insults that may operate early in pregnancy.

On the basis of these observations, we have now gone on to review the current experimental literature to gain insight into potential mechanisms for in utero cardiovascular programming in relation to pre-eclampsia. We have focused on experiments that use models designed to replicate features of pre-eclampsia, in particular the early detrimental exposures that characterize the fetal experience in this condition. We have compared the findings with those from human studies of offspring, or tissues, from pre-eclamptic pregnancies. The cumulative body of work supports associations between pre-eclampsia exposure and offspring cardiovascular health, as well as a potential pivotal role for long-term programmed changes in vascular biology (Table 1 and Figure 1).


Disturbed placentation in early pregnancy is considered the key pathological event that leads to subsequent development of pre-eclampsia [2,33]. Normal placental development is characterized by invasion of maternal spiral arteries by fetal cytotrophoblasts and their transformation into high-calibre capacitance vessels, which provides low-resistance placental perfusion to sustain fetal growth [34]. In pre-eclampsia, the spiral arteries inadequately remodel so that uterine flow is reduced by 50% and there is chronic placental ischaemia or, at best, intermittent flow that induces an ischaemia/reperfusion phenomenon [35]. ROS (reactive oxygen species) and cytokines released from the ischaemic placenta trigger a systemic oxidative [36] and inflammatory [35,37] state. The placenta also overexpresses anti-angiogenic factors that inhibit the normal function of pregnancy-related pro-angiogenic factors, including VEGF (vascular endothelial growth factor) and PlGF (placental growth factor) [38]. The combination of these factors is believed to underlie the systemic endothelial dysfunction that is consistently found during symptomatic pre-eclampsia in the mother.

Offspring of pre-eclamptic pregnancies therefore develop from the first trimester onwards within an environment of placental insufficiency and restricted oxygen supply. By the start of the second trimester there is, in addition, exposure to elevated circulating anti-angiogenic factors, which predates the later emergence of the clinical pre-eclamptic syndrome and the diffuse maternal inflammatory, oxidative and dysfunctional endothelial state. Experimental studies have an important role to help us understand how, and whether, these specific insults have an impact on the developing cardiovascular system of the offspring. Their findings have the potential to unravel the developmental programming that underlies the observed long-term cardiovascular disease risk in the offspring.

However, the ideal animal model of pre-eclampsia does not exist, in part because the spontaneous development of pre-eclampsia during pregnancy is a condition largely unique to humans [39,40]. To mimic the human syndrome a model would need to be characterized by the development of pregnancy-specific hypertension, proteinuria and associated alterations in vascular function and biomarkers. To replicate the condition perfectly, these changes must be secondary to impaired trophoblastic invasion [40]. Although a variety of models based on different aspects of the pathophysiology of pre-eclampsia exist [39,40], no model has been able to successfully mimic all of the pathophysiological features of pre-eclampsia or to accurately replicate the first trimester origin of the human condition. For example, the currently available animal models are limited in their capacity to produce the metabolic alterations which are evident in human pre-eclamptic pregnancies [41,42]. Another limitation is that the models have been primarily developed to investigate pre-eclampsia in the mother not the offspring. However, fortuitously, the adequacy of animal models developed to study pre-eclampsia has, in part, been defined by their ability to induce IUGR. As a result, these ‘pre-eclampsia’ models have been adopted to study how IUGR has an impact on the offspring [43]. The findings from these offspring studies, in particular those that maintain experimental set ups that would be expected to induce pre-eclampsia-like syndromes in the dams, thereby provide insights into the role of pre-eclampsia-related insults. We have used data available from animal models to dissect out whether there is evidence that key features of the pre-eclamptic in utero environment induce long-term changes characteristic of the cardiovascular risk phenotype seen in offspring of pre-eclamptic pregnancies, namely elevated resting BP.

Uterine perfusion

Mechanical reduction in maternal uterine artery blood flow [RUPP (reduced uterine artery perfusion)], by unilateral or bilateral uterine artery ligation, in animal models induces a pregnancy-specific increase in maternal BP [44]. The model is well established and has been applied in a range of species from initial work in dogs to rats [40], rabbits [45], sheep [46], guinea-pigs [47] and non-human primates [48]. In dogs, other cardinal features of pre-eclampsia are evident such as renal glomerular endotheliosis and, in some instances, proteinuria [49]. In rats, RUPP pressure between days 14 and 19 of pregnancy induces a full pre-eclampsia pregnancy phenotype, including markedly elevated BP and changes in renal artery flow and glomerular filtration rate [50]. Furthermore, other distinct biological changes occur in the mother, specifically dysfunction of endothelium-dependent vascular relaxation [51,52] and increased circulating levels of sFlt-1 (soluble fms-like tyrosine kinase-1) with a resultant reduction in VEGF and PlGF [53].

Variations of the RUPP model have been used to study the influence of reduced uterine perfusion on offspring BP and, interestingly, BP does not differ from controls in a large number of the studies [5462]. Variation in the species investigated or techniques for BP measurement have been postulated to account for this disparity from the observations in humans. However, when all of the studies are considered together (Figure 2), the time when uterine perfusion is reduced appears to be critical. If at 14 days into gestation, changes in resting BP are consistently evident in the offspring throughout life. When uterine perfusion is only introduced late in gestation, despite inducing growth restriction, the studies show either no increase in BP or modest changes in later life that may require stimuli to elicit variability [6365]. These findings argue for early exposure to uterine perfusion abnormalities to be critical to the BP programming in the offspring. However, early ligation has been associated with the full range of pre-eclampsia-like features in the dams, including deranged anti-angiogenic factors and vascular dysfunction. Therefore an evaluation of the specific relevance of the individual insults is not possible from this model.


Placental insufficiency is likely to lead to offspring of pre-eclamptic pregnancies developing in an environment of significant hypoxia from early in pregnancy. In all pregnancies, early placental development takes place under low oxygen conditions as this predates the formation of an effective maternal–fetal circulation [66,67]. Even in later stages of normal pregnancy, fetuses whose mothers have normal placental perfusion and breathe 21% inspired O2 are still exposed to intervillous oxygen levels equivalent to only 8–11% O2. The abnormal placentation in pre-eclampsia is therefore likely to result in significantly lower oxygen delivery to the fetus for the majority of gestation. Interestingly, even in pregnant mice with normal placental development, exposure to an inappropriate level of hypoxia from early in pregnancy (9.5% O2 from day 7.5 to day 17 of gestation) induces a range of pre-eclampsia-like symptoms in the mother, including hypertension, proteinuria, IUGR, renal pathology and elevations in maternal sEng (soluble endoglin) [68]. The underlying reason for this is not clear, although it could be because the degree of hypoxia induced at the level of the placenta is sufficient to trigger the ‘pre-eclampsia cascade’ of events, similar to that present in a mother with abnormal placental development. Consistent with this hypothesis, less severe hypoxia (11% O2) or hypoxia later in gestation (9.5% O2 from day 10 or 15 to day 17 of gestation) does not induce these changes [68].

When the data from models of pregnancy hypoxia are collated (Figure 3), despite a range of changes in other cardiovascular measures, there is a striking lack of any consistent reports of elevated BP in the offspring. This may be because the majority of studies are based on the use of oxygen concentrations higher than 9.5% and/or exposed animals later in pregnancy [6971]. Even in models in which oxygen availability is reduced early in development (days 5–20 of pregnancy), the level of maternal hypoxia (10% O2) has been relatively higher than that normally associated with induction of a pre-eclampsia-like syndrome in the mother. BP variation in the offspring has been demonstrated in response to stress [72], but this BP phenotype is distinct from that observed in human offspring of pre-eclamptic pregnancies, who have increased resting BP in early life [18]. These findings may suggest that hypoxia alone is insufficient to induce the long-term effects of pre-eclampsia seen in the offspring, or that the levels of hypoxia currently used are not representative of the levels offspring are exposed to during development.

Anti-angiogenic factors

Multiple studies have now demonstrated a key step in the progression of pre-eclampsia from placental underperfusion and hypoxia to a clinical syndrome is an increase in levels of circulating anti-angiogenic factors. These include sFlt-1, the alternatively spliced truncated form of VEGF receptor 1 [73], and sEng [7476]. sFlt-1 inhibits the normal function of pregnancy-related angiogenic factors, including VEGF and PlGF [38], and a Sprague–Dawley model of pre-eclampsia based on adenovirus vector administration of sFlt-1 early in the second trimester (days 8–9 of pregnancy), when the levels are seen to increase in human pregnancy, has been developed [74]. This model overexpresses sFlt-1 and the transfected rats develop hypertension, heavy proteinuria and glomerular endotheliosis. These signs also occur in non-pregnant rats treated with sFlt-1 [74], indicative of the broader relevance of deranged anti-angiogenic factors to vascular homoeostasis. The same intervention in mice induces a slightly different phenotype with maternal hypertension, fetal growth restriction and impairment of maternal platelet count [77]. Lu et al. [78] have investigated the effect of administration of an adenovirus carrying sFlt-1 to pregnant mice on offspring BP over the first 6 months of life. They found a sustained increase in BP in male offspring evident from the first day of life, which persisted during the period of measurement. As with other models of pre-eclampsia, a range of clinical features of the condition are induced [79] and specific culpability for sFlt-1 in programming of offspring cardiovasculature cannot be confirmed. Nevertheless, the results suggest that, even with normal placentation and uterine blood flow in early pregnancy, exposure to an excess of anti-angiogenic factors, specifically raised sFlt-1 and its biological sequelae, is sufficient to induce long-term changes in BP in the offspring.

Systemic endothelial dysfunction

The specific role of systemic maternal endothelial dysfunction is relatively simpler to explore. This is because targeted animal models are available that allow in utero development in a mother with endothelial dysfunction to be studied. These models are based either on systemic inhibition of eNOS (endothelial NO synthase) by administration of L-NAME (NG-nitro-L-arginine methyl ester) or by eNOS knockout [39]. A limitation is that these are not good models of pre-eclampsia itself as the hypertension in eNOS-knockout mice [80] is not pregnancy-specific and, indeed, one study has reported that eNOS-knockout mothers have no difference in BP during pregnancy [81]. Nevertheless, the mice consistently exhibit abnormal endothelial function and, through selective breeding of an eNOS-knockout mother with a wild-type male, an experimental scenario can be generated to study the impact of maternal endothelial dysfunction on the in utero development of an eNOS-heterozygous offspring (Figure 4). These offspring have higher BP during adulthood than the genetically similar offspring bred from a wild-type mother and an eNOS-knockout father, who differ only in that their in utero development was in a wild-type mother with normal endothelial responses [82]. Such findings highlight the potential pivotal importance of maternal endothelial dysfunction during pregnancy, even in the absence of other pre-eclamptic features, on long-term offspring outcome.


The data from available animal models implicate reduced uterine perfusion, if present from early in pregnancy, as well as exposure to anti-angiogenic factors and systemic endothelial dysfunction, from at least the second trimester, as capable of inducing long-term changes in BP in offspring. The evidence for a specific effect of hypoxia is weaker in current animal models, although some changes in BP response if hypoxia occurs from early in pregnancy is observed. To understand how these insults during pregnancy might lead to long-term alterations in BP, a more in-depth study of the cardiovascular phenotype that might be relevant to BP in these experimental models is required.

Vascular structure

A key determinant of BP in humans is arterial stiffness, with increased arterial stiffness being associated with elevation of central BPs [83,84]. Therefore one possibility is that exposure to the abnormal intra-uterine milieu of pre-eclampsia leads to vascular structural remodelling that persists into post-natal life [85]. One RUPP model study has evaluated the stress–stain relationship of offspring arteries and found evidence of increased aortic stiffness, as well as greater elastic fibre content in the vessel wall [63]. Apparently in support of the hypothesis that pre-eclamptic insults induce structural changes in blood vessels are findings from a guinea-pig model of RUPP-exposed offspring, which showed increased thickness of the aortic media [86]. Offspring of dams, hypoxic from early in gestation, were also found to have a thicker aortic media with increased smooth muscle cell density in fetal life [87,88]. However, changes in arterial stiffness are not found in studies of human offspring in adolescence (14 years of age) [11] or young adulthood (20–30 years of age) [12] and, in animal models, by adult life, 16-month-old offspring of hypoxic dams start to exhibit quite distinct vascular structural changes with oedematous and necrotic aortic endothelium and disarranged proliferative smooth muscle cells [89]. These findings are more characteristic of atherogenic vascular remodelling rather than the vascular structural matrix changes associated with abnormal arterial stiffness [84]. Other studies of rat RUPP offspring have also identified an increased propensity to develop arterial internal elastic lamina lesions, an early atherosclerotic process, when studied at 8 and 16 weeks of age [64].

These observations highlight development of an early atherogenic phenotype, independent of BP, as an additional potential link between pre-eclampsia exposure and later cardiovascular disease. Atherosclerosis in humans is characterized by thickening of the arterial intima media, which can be evaluated non-invasively by ultrasound [90], and carotid artery IMT (intima-media thickness) associates with the extent of coronary artery disease [90,91]. Consistent with the observations in animal studies, offspring of pre-eclamptic pregnancies also show an increased IMT in their 20s [12] with aortic arterial thickening already evident at birth [92]. Therefore the features of vascular remodelling that have been observed are predominantly not those associated with the arterial stiffening that underlies BP variation. However, there appear to be significant early atherosclerosis-related changes in the vascular wall, the importance of which require further exploration.

Cardiac structure

An alternative possibility to explain the variation in BP is that the in utero insult alters cardiac development. The structural and functional changes, such as increased cardiac output or LVH [LV (left ventricular) hypertrophy], then predispose to development of hypertension [93]. Hypoxic exposure in pregnancy does lead to abnormalities in cardiac appearances, although these seem to be predominantly of a cardiomyopathic phenotype more commonly linked with the development of heart failure. Rat offspring exposed to hypoxia during late gestation have increased cardiac size relative to body weight [89,9496], with reduced LV wall thickness, reduced cardiomyocte proliferation and epicardial detachment [96,97]. It has been hypothesized that this detachment of the epicardium in fetal life [97] may be mechanistically related to the changes in the myocardium, as the epicardium is a major source of growth factors during cardiac development [96,97]. Higher levels of apoptotic proteins and induction of HIF (hypoxia-inducible factor)-1α are also evident and may drive some of this process [98,99].

Additionally, offspring cardiac collagen content can be altered by maternal hypoxia, with rats exposed to hypoxia during late gestation having increased cardiac levels of collagen I and III [96,100]. These animals express a complex array of alterations in extracellular matrix regulation so that, by day 21, rat fetuses exposed to hypoxia have decreased MMP (matrix metaloproteinase)-1 and increased MMP-13 and TIMP (tissue inhibitor of metalloproteinases)-3 and TIMP-4. In neonatal life, both MMP-1 and MMP-13 levels are still raised and at 4 months of age MMP-2 levels are reduced [96,100]. Another potential link between in utero hypoxia and later cardiovascular disease is through alterations in cardiac ischaemia/reperfusion mechanisms. Specifically, rats exposed to hypoxia in late gestation have been found to have alterations in cardiac proton production and increased myocardial production of acetyl-CoA during reperfusion [94,99]. In fetal life, such animals also have a significant reduction in cardiac PKCϵ (protein kinase Cϵ), possibly secondary to increased methylation at the PKCϵ promoter site [101]. As PKCϵ plays a critical role in cardioprotection during ischaemia [102], this may underlie the observed differences.

However, these findings need to be interpreted with caution in relation to pre-eclampsia. None of the studies have investigated low levels of hypoxia early in pregnancy and the data for long-term changes in cardiac function are variable. Offspring of Sprague–Dawley rats exposed to hypoxia (12% O2) from days 15 to 21 of pregnancy showed no differences from controls in cardiac function at 4 months of age, as assessed by echocardiography, but, by 12 months, male offspring only demonstrated signs of LVH. In a second study, both male and female offspring had structurally similar hearts, but those exposed to hypoxia had impaired diastolic function and evidence of pulmonary hypertension in later life [95].

In humans, placental tissue from pre-eclamptic pregnancy has differential expression of genes associated with cardiovascular development [103]. However, an 18-year follow-up of children born to hypertensive pregnancies did not show differences in LV mass, as assessed by echocardiography [104]. More recently, one study in children aged 5–8 years exposed to pre-eclampsia in utero found they had smaller hearts, increased heart rate and increased late diastolic velocity at the mitral valve attachments [105]. Overall, a pragmatic conclusion is that more detailed work is needed to understand whether pre-eclampsia leads to cardiac changes in humans. If so, the geometric cardiac changes observed so far are likely to be a distinct pathway to disease, or secondary to BP variation, rather than the primary underlying mechanism for the hypertensive phenotype of the offspring of pre-eclamptic pregnancies.

Vascular function

One possibility is that the variation in BP is driven by underlying induced abnormalities in vascular function, rather than structural cardiovascular changes. In particular, systemic endothelial function is associated with traditional cardiovascular risk factors, including hypertension [106]. Endothelial dysfunction is also an early biological factor in the development of atherosclerotic vascular disease [107,108] and predisposes to the development of LVH [109]. Consistent with vascular function being a central factor in the association between pre-eclampsia and long-term cardiovascular health, abnormalities in vascular responses are found in nearly all offspring models that mimic pre-eclampsia, as well as the majority of human studies of offspring of pre-eclamptic pregnancies. RUPP offspring have enhanced vascular contraction in response to phenylephrine and a reduction in endothelium-dependent relaxation during early life [54,63,110]. Lower flow-mediated vasodilation is also evident up to 12 months of age in rats born to mothers housed under hypoxic conditions, even if only during late gestation (days 15–21 of pregnancy) with relatively high oxygen levels (11.5–12% O2) [69,70]. In more specific ‘pre-eclampsia’ models, long-term effects on endothelial responses are the major adverse change reported in cardiovascular phenotype of male offspring of sFlt-1-induced ‘pre-eclamptic’ mothers. They exhibit the same pattern of higher responses to phenylephrine and reduced vasorelaxation in response to acetylcholine [111] observed in the RUPP offspring model. Mice heterozygous for eNOS, whose mothers were eNOS-knockout and therefore who developed in an in utero environment of endothelial dysfunction, similarly have enhanced phenylephrine-induced contraction and reduced acetylcholine-mediated relaxation compared with heterozygous mice with wild-type mothers [112,113].

This finding is also evident in humans, with young adults (20–30 years of age) born pre-term to hypertensive pregnancies having a distinct vascular phenotype when compared with those born pre-term to normotensive pregnancies, despite both groups demonstrating a similar magnitude of increase in BP when compared with term-born controls [12]. Only those born to hypertensive pregnancies had evidence of impaired flow-mediated endothelial responses. Offspring of pre-eclamptic women also have impaired endothelial function in childhood (5–8 years of age) [114] and adolescence (14 years of age) [11]. Only one study, in children between 9 and 10 years of age, has not been able to demonstrate this difference in endothelial response [15]. Recently, it has been reported that there are endothelium-dependent differences evident within the microvasculature in offspring of pre-eclamptic pregnancies during neonatal life [115], and evidence has been found of endothelial activation at birth based on cord blood analysis [116].

Experimental studies provide some insight into the potential underlying vascular abnormality. In arterial segments from RUPP model offspring, both basal and acetylcholine-induced NO production is reduced and arterial segments from RUPP animals do not demonstrate the normal impairment of acetylcholine-induced vasodilation after L-NAME pre-treatment [54]. This latter observation suggests there may also be a compensatory up-regulation of NO-independent pathways to maintain the vasodilation response. This loss of NO-mediated vasomodulation due to reduced NO production also underlies the vascular dysfunction demonstrated in several studies of rats exposed to hypoxia in utero [6971,117] and has been observed in studies of HUVECs (human umbilical vein endothelial cells) grown from umbilical cords from pre-eclamptic pregnancies [118].

What might underlie the reduced NO synthesis? A characteristic feature of pre-eclampsia is a derangement of circulating anti-angiogenic factors. Elevated sEng in the pre-eclamptic mother, with resultant alterations in TGF (transforming growth factor)-β signalling, has been directly implicated in reduced NO bioavailability in the mother. Persistent abnormalities in anti-angiogenic factors in the offspring could therefore lead to persistent endothelial dysfunction in later life. Studies during neonatal life demonstrate that the fetus is exposed to elevated anti-angiogenic factors in utero, as amniotic fluid levels of sFlt-1 are higher in pre-eclamptic pregnancies [119] and neonates born to pre-eclamptic pregnancies have significantly higher circulating sFlt-1 and sEng, as well as lower VEGF and PlGF levels [120,121]. However, to date, the only study of anti-angiogenic factors in children of 5–8 years of age has demonstrated no long-term differences [114].

One possibility is that in utero exposure to anti-angiogenic factors leads to altered in utero endothelial development and physiology. Consistent with this hypothesis, sFlt-1 administered in vitro inhibits endothelial cell proliferation and tubule formation [122]. HUVECs from pre-eclamptic donors also appear to differ from normal in their response to oxygen levels. Under normoxic conditions, they develop a higher numbers of connections and shorter tubule lengths, creating networks similar to those seen when control cells were grown under hypoxic conditions [118]. These findings suggest that endothelial cells from pre-eclamptic pregnancies may be fixed in a ‘hypoxic’ phenotype. This ‘hypoxic’ programming may not be endothelium-specific, as gene expression in pre-eclamptic placentae is also similar to that seen in control placental explants grown at 3% O2 [67], and metabolomic studies have demonstrated that pre-eclamptic placental tissue grown under normoxic conditions behaves similarly to control tissue grown under hypoxia [123].

Another possibility is that the endothelial dysfunction represents a biomarker of other underlying metabolic abnormalities related to cardiovascular disease. However, there is limited evidence that pre-eclampsia leads to the metabolic syndrome in the offspring [18,124], with no convincing evidence for changes in serum lipids or glucose tolerance beyond acute transient changes in cord blood samples [12,14,15,114,125130]. Animal studies of maternal hypoxia suggest that it is possible to induce metabolic changes in animals exposed to a high-fat diet, leading to increased serum leptin, triacylglycerols (triglycerides), non-esterified (‘free’) fatty acids and impaired glucose tolerance [131]. However, the need for a secondary inducer would suggest that lipid and glucose abnormalities are not fundamental features of the underlying hypertensive cardiovascular phenotype.

Alternatively, the vascular changes could be inherited between mother and child. Polymorphisms in certain genes, such as those encoding eNOS, ACE (angiotensin-converting enzyme) and angiotensin, have been proposed as potential links [132] underlying the development of the condition, although no consistent associations have been found [133]. Adverse exposures during fetal life could also lead to heritable characteristics through programming of the epigenome, as the greatest level of active programming of the epigenome occurs during fetal life [134]. This is clearly possible in humans, as placental DNA is hypomethylated following early-, but not late-, onset pre-eclampsia [135,136] and imprinting of non-coding RNA in placental tissue also differs in studies of pre-eclamptic tissues [137]. As epigenetic changes are potentially dynamic [138,139], this mechanism is of interest as a target for intervention [140]. Transgenerational, potentially epigenetic, effects are seen in ‘pre-eclampsia’ models. Elevated BP is evident in the first 12 weeks of life in both male and female second-generation offspring born to RUPP offspring [141]. Such transgenerational effects are also evident in eNOS-knockout models as second-generation offspring born to the eNOS-heterozygous mothers, who developed in an in utero environment of endothelial dysfunction, have increased BP compared with those born to genetically similar mothers who had a normal in utero development.

A potential stimulus for epigenetic programming is hypoxia, which has been shown to induce a global decrease in transcriptional activity in the vascular endothelium [142]. Alternatively, the systemic maternal oxidative stress evident during pre-eclampsia could alter the delicate balance between the production of ROS and cellular defences in the neonate. Oxidative stress has been suggested to influence histone acetylation and phosphorylation [143], telomere length [144] and vascular gene expression. Some oxidative stress is required for normal fetal development [145], but the ischaemic pre-eclamptic placenta has significantly decreased total antioxidant capacity compared with the normal placenta, and there is a correlation between levels of oxidative stress in maternal peripheral blood and cord blood in normotensive and pre-eclamptic pregnancies [146,147], with levels significantly higher in pre-eclampsia [127,147]. The levels of oxidative stress induced by pre-eclampsia itself are sufficient to cause damage to the fetus, as placental tissue samples have higher levels of oxidative DNA damage in pre-eclamptic pregnancies, whether or not there has been fetal growth restriction [148]. This independent effect of pre-eclampsia is not surprising, as fetal antioxidant capacity generally only increases in the last trimester after the increase in oxidative stress observed in early-onset pre-eclampsia [127,149]. Mitochondrial oxidative species may be particularly relevant to this fetal programming mechanism as, following pre-eclampsia, fetal-derived HUVECs have impaired mitochondrial function [150] associated with increased endothelial mitochondrial oxidative species generation.

Altered sympatho-adrenal function

It is also possible that the increased BP following in utero exposure to pre-eclampsia is explained, in part, by non-vascular alterations. The sympathetic nervous system has a key role in regulating BP in humans and overactivity may be associated with development of hypertension [151]. Heart rate variability, a marker of autonomic nervous system function, has been associated with and precedes the development of several cardiovascular risk factors, as well as being a predictor of mortality in high- and low-risk populations [152]. Furthermore, alterations in adrenal function have been associated with features of the metabolic syndrome in adults [153]. Tenhola et al. [14,154] have suggested that, in childhood, children born to a pre-eclamptic mother have increased serum adrenaline, but were not able to demonstrate differences in other adrenal hormones. Despite this lack of human data, there is some supportive evidence from animal models. In particular, hypoxia studies have considered sympatho-adrenal function in both fetal and post-natal life. A chick embryo that has developed at high altitude, and therefore has been exposed to significant hypoxia throughout gestation, has elevated plasma corticotrophin, decreased plasma corticosterone and elevated adrenal adrenaline and noradrenaline compared with those incubated at sea level [155]. Fetuses of pregnant ewes who undergo gestation at high altitude similarly had reduced adrenal mRNA for CYP (cytochrome P450) 17, CYP11A1 and ACTH (corticotropin) [156], and higher eNOS expression in the inner adrenal cortex [157]. There is some evidence that these alterations in sympatho-adrenal programming also persist through post-natal life, as the offspring of Sprague–Dawley rats exposed to hypoxia from pre-natal days 5–20 demonstrate persistent alterations in the levels and utilization of catecholamines in the heart and stellate ganglion at 12 weeks of age [72]. Even shorter exposures later in pregnancy may effect adrenal function, as exposure of rat fetuses to 12% O2 in the last 3 days of gestation led to altered aldosterone levels at 7 days of age [158]. Further studies will be required to elucidate whether this mechanism is significant in humans.

Renal dysfunction

Another possibility is that changes in renal function are central to the programming of hypertension in offspring of pre-eclamptic pregnancies. Offspring of the rat RUPP model have inhibition of the RAS (renin–angiotensin system), and bilateral renal denervation normalizes their BP without influencing BP in control animals [61,62]. RUPP offspring also have reductions in glomerular number [57,65,159], increased glomerular collagen deposition [86], increased glomerular volume [57,159,160], altered renal VEGF expression [161] and alterations in intrarenal renin and angiotensin expression [61], although no difference in plasma renin activity has been demonstrated [59,60,162]. At 18 months of age, female RUPP offspring have increased plasma creatinine and renal expression of TGF-β, MMP-9 and type VI collagen [65]. Additionally, RUPP offspring have reduced renal expression of the glucocorticoid receptor at day 21 after birth and increased mineralocorticoid receptor expression at birth compared with control animals [160]. Similar findings have never been demonstrated in humans, but conceivably these changes would be relevant to BP control and a further understanding of the potential role of pre-eclampsia-induced renal changes in humans subjects requires investigation [163].

Altered immune function and inflammation

Finally, evidence for a further non-vascular non-hypertension pathway of relevance to cardiovascular disease development in the offspring of pre-eclamptic pregnancy has recently emerged. Integration of data from genome-wide gene expression studies of pre-eclamptic decidua basalis tissue with tissue from subjects with a history of familial heart disease has identified commonality between disease processes and several differentially expressed genes relevant to immune function and inflammatory responses [164]. These include NOD1 [NOD (nucleotide-binding and oligomerization domain)-like receptor 1], which plays a key role in intracellular innate immunity [165], and SPPL2 (signal peptide peptidase-like 2), which has been shown to play a role in the release of pro-inflammatory cytokines [166]. Pre-eclampsia involves a range of key immune responses at different stages of the syndrome [34], with the final symptomatic phase characterized by an intense maternal systemic inflammatory response [34]. Women who suffer from autoimmune conditions are at an increased risk of developing pre-eclampsia [167], and in animal models the transfer of activated Th1 cells or infusion of inflammatory cytokines induces pre-eclampsia-like symptoms [168170]. Inflammation has a key role in cardiovascular disease, with inflammatory cell infiltration of the vessel wall an early pathophysiological stage in the development of atherosclerotic cardiovascular disease [171,172]. Interestingly, neonates born following pre-eclamptic pregnancies have elevated IL (interleukin)-8 and greater percentages of natural killer cells, reduced number of T-cells and altered expression of the Fas/Fas ligand in their umbilical cord blood [173176]. However, without longer term follow-up it is difficult to determine whether these changes reflect acute changes associated with the pregnancy or long-term changes relevant to disease. A single study of 5–8-year-old children born to women who experienced pre-eclampsia showed no difference in general systemic inflammation, assessed by high-sensitivity CRP (C-reactive protein) [114], but more sophisticated immunological or inflammatory markers were not considered. Nevertheless, given the growing understanding of the importance of inflammation and immune function in the pathophysiology of pre-eclampsia and cardiovascular disease, further investigation of these factors may prove useful in understanding the links between pre-eclampsia and offspring cardiovascular health.

Gender differences and the effect of hormonal status

In addition to other potential programming mechanisms, some studies have suggested the association between exposure to pre-eclampsia and alteration of offspring phenotype may be sex-specific. Animal work suggests that hormonal status may play some role in phenotypic modulation. Lu et al. [78] have demonstrated that the male offspring of sFlt-1-induced ‘pre-eclamptic’ mothers demonstrated a sustained increase in BP from the first day of life, which was not shown in female offspring [78]. The hormonal status of RUPP offspring may play a significant role, as castration of male RUPP offspring has been demonstrated to normalize BP [162], whereas ovarianectomy induced hypertension in otherwise normotensive female RUPP offspring [60]. Such findings suggest that gender-specific hormone expression may mediate or alter the phenotype associated with exposure to adverse intra-uterine conditions. Some human studies of BP in children born to pre-eclamptic mothers have also demonstrated gender differences; however, these differed with some showing elevation in males and some in females [177179]. A recent meta-analysis of data considering BP in children born to pre-eclamptic pregnancies has suggested that the phenotype is similar in both males and females [18]. Despite this, the findings from animal models arguably suggest that gender-related changes in biology may require closer investigation in relation to other aspects of the phenotype in human populations.


Pre-eclampsia has a long-term impact on the cardiovascular health of both mother and offspring. The pre-eclamptic in utero environment is characterized by reduced uterine perfusion, hypoxia, raised anti-angiogenic factors and systemic oxidative stress, leading to maternal endothelial dysfunction. Animal studies support the potential relevance of these insults to programming of offspring BP and, in combination with human experimental studies, have demonstrated a range of potential mechanisms for the hypertensive phenotype. In particular, endothelial dysfunction is consistently observed in offspring of both animal and human studies well into adult life. The underlying programming of vascular function may relate to ‘structural’, ‘hypoxic’ or ‘epigenetic’ programming of endothelial development and physiology. In addition, complementary pathways to disease development, including changes in cardiac function, accelerated atherogenesis or alterations in renal and immune function, may emerge as relevant to later disease in offspring of pre-eclamptic pregnancies. Greater understanding of all of these mechanisms will provide the basis for future novel strategies to prevent cardiovascular disease in this high-risk group.


This review is part of a programme of work supported by the British Heart Foundation (BHF) [grant numbers FS/06/024 and FS/11/65/28865], the NIHR Oxford Biomedical Research Centre and the Oxford BHF Centre for Research Excellence (to P.L.). E.F.D. is supported by a Clarendon Scholarship and A.J.L. by a Commonwealth Commission Scholarship.

1. Wen S. W.,Chen X.-K.,Rodger M.,Rennicks White R.,Yang Q.,Smith G. N.,Sigal R. J.,Perkins S. L.,Walker M. C.. Folic acid supplementation in early second trimester and the risk of preeclampsiaAm. J. Obstet. Gynecol.Year: 200819845.e4145.e4718166303
2. Steegers E.A.P.,von Dadelszen P.,Duvekot J. J.,Pijnenborg R.. Pre-eclampsiaLancetYear: 201037663164420598363
3. Bellamy L.,Casas J.-P.,Hingorani A. D.,Williams D. J.. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysisBMJYear: 200733597417975258
4. McDonald S. D.,Malinowski A.,Zhou Q.,Yusuf S.,Devereaux P. J.. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analysesAm. Heart J.Year: 200815691893019061708
5. Ferreira I.,Peeters L. L.,Stehouwer C. D.. Preeclampsia and increased blood pressure in the offspring: meta-analysis and critical review of the evidenceJ. Hypertens.Year: 2009271955195919893428
6. Kajantie E.,Eriksson J. G.,Osmond C.,Thornburg K.,Barker D.J. P.. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki Birth Cohort StudyStrokeYear: 2009401176118019265049
7. Vatten L. J.,Romundstad P. R.,Holmen T. L.,Hsieh C.-c.,Trichopoulos D.,Stuver S. O.. Intrauterine exposure to preeclampsia and adolescent blood pressure, body size, and age at menarche in female offspringObstet. Gynecol.Year: 200310152953312636958
8. Ogland B.,Vatten L. J.,Romundstad P. R.,Nilsen S. T.,Forman M. R.. Pubertal anthropometry in sons and daughters of women with preeclamptic or normotensive pregnanciesArch. Dis. Child.Year: 20099485585919574235
9. Kvehaugen A. S.,Andersen L. F.,Staff A. C.. Dietary intake and physical activity in women and offspring after pregnancies complicated by preeclampsia or diabetes mellitusActa Obstet. Gynecol. Scand.Year: 2010891486149020955103
10. Geelhoed J. J. M.,Fraser A.,Tilling K.,Benfield L.,Davey Smith G.,Sattar N.,Nelson S. M.,Lawlor D. A.. Preeclampsia and gestational hypertension are associated with childhood blood pressure independently of family adiposity measures: the Avon Longitudinal Study of Parents and ChildrenCirculationYear: 20101221192119920823385
11. Jayet P.-Y.,Rimoldi S. F.,Stuber T.,Salmon C. S.,Hutter D.,Rexhaj E.,Thalmann S.,Schwab M.,Turini P.,Sartori-Cucchia C.,et al. Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsiaCirculationYear: 201012248849420644018
12. Lazdam M.,de la Horra A.,Pitcher A.,Mannie Z.,Diesch J.,Trevitt C.,Kylintireas I.,Contractor H.,Singhal A.,Lucas A.,et al. Elevated blood pressure in offspring born premature to hypertensive pregnancy: is endothelial dysfunction the underlying vascular mechanism?HypertensionYear: 20105615916520479334
13. Seidman D. S.,Laor A.,Gale R.,Stevenson D. K.,Mashiach S.,Danon Y. L.. Pre-eclampsia and offspring's blood pressure, cognitive ability and physical development at 17-years-of-ageBr. J. Obstet. Gynaecol.Year: 199198100910141751432
14. Tenhola S.,Rahiala E.,Martikainen A.,Halonen P.,Voutilainen R.. Blood pressure, serum lipids, fasting insulin, and adrenal hormones in 12-year-old children born with maternal preeclampsia. J. Clin. EndocrinolMetab.Year: 20038812171222
15. Lawlor D. A.,Macdonald-Wallis C.,Fraser A.,Nelson S. M.,Hingorani A.,Davey Smith G.,Sattar N.,Deanfield J.. Cardiovascular biomarkers and vascular function during childhood in the offspring of mothers with hypertensive disorders of pregnancy: findings from the Avon Longitudinal Study of Parents and ChildrenEur. Heart J.Year: 20123333534521862461
16. Øglænd B.,Forman M. R.,Romundstad P. R.,Nilsen S. T.,Vatten L. J.. Blood pressure in early adolescence in the offspring of preeclamptic and normotensive pregnanciesJ. Hypertens.Year: 2009272051205419609220
17. Leeson P.. Pediatric prevention of atherosclerosis: targeting early variation in vascular biologyPediatricsYear: 20071191204120617545390
18. Davis E. F.,Lazdam M.,Lewandowski A. J.,Worton S. A.,Kelly B. A.,Kenworthy Y.,Adwani S.,Wilkinson A. R.,McCormick K.,Sargent I.,et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic reviewPediatricsYear: 2012 doi:10.1542/peds.2011-3093.
19. Chen X.,Wang Y.. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysisCirculationYear: 20081173171318018559702
20. NICEHypertension (Update)Year: 2011LondonNational Institute for Health and Clinical Excellence
21. Williams P. J.,Broughton Pipkin F.. The genetics of pre-eclampsia and other hypertensive disorders of pregnancyBest Pract. Res. Clin. Obstet. Gynaecol.Year: 20112540541721429808
22. Warner M. J.,Ozanne S. E.. Mechanisms involved in the developmental programming of adulthood diseaseBiochem. J.Year: 201042733334720388123
23. Lucas A.. Programming by early nutrition in manCiba Found. Symp.Year: 199115638501855415
24. Bonamy A.-K. E.,Norman M.,Kaijser M.. Being born too small, too early, or both: does it matter for risk of hypertension in the elderly?Am. J. Hypertens.Year: 2008211107111018704113
25. Barker D. J. P.. Fetal origins of coronary heart diseaseBr. Med. J.Year: 19953111711747613432
26. Barker D. J.,Bull A. R.,Osmond C.,Simmonds S. J.. Fetal and placental size and risk of hypertension in adult lifeBr. Med. J.Year: 19903012592622390618
27. Barker D. J.,Hales C. N.,Fall C. H.,Osmond C.,Phipps K.,Clark P. M.. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growthDiabetologiaYear: 19933662678436255
28. Norman M.. Preterm birth: an emerging risk factor for adult hypertension?Semin. Perinatol.Year: 20103418318720494733
29. Huxley R. R.,Shiell A. W.,Law C. M.. The role of size at birth and postnatal catch-up growth in determining systolic blood pressure: a systematic review of the literatureJ. Hypertens.Year: 20001881583110930178
30. van der Merwe J. L.,Hall D. R.,Wright C.,Schubert P.,Grové D.. Are early and late preeclampsia distinct subclasses of the disease-what does the placenta reveal?Hypertens. PregnancyYear: 20102945746720701467
31. Touwslager R. N.,Houben A. J.,Gielen M.,Zeegers M. P.,Stehouwer C. D.,Zimmermann L. J.,Kessels A. G.,Gerver W. J.,Blanco C. E.,Mulder A. L.. Endothelial vasodilatation in newborns is related to body size and maternal hypertensionJ. Hypertens.Year: 201131124131
32. Singhal A.,Kattenhorn M.,Cole T. J.,Deanfield J.,Lucas A.. Preterm birth, vascular function, and risk factors for atherosclerosisLancetYear: 20013581159116011597675
33. Kanasaki K.,Kalluri R.. The biology of preeclampsiaKidney Int.Year: 20097683183719657323
34. Redman C. W. G.,Sargent I. L.. Immunology of pre-eclampsiaAm. J. Reprod. Immunol.Year: 20106353454320331588
35. Redman C. W. G.,Sargent I. L.. Placental stress and pre-eclampsia: a revised viewPlacentaYear: 2009303842
36. Rodie V. A.,Freeman D. J.,Sattar N.,Greer I. A.. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy?AtherosclerosisYear: 200417518920215262174
37. Poston L.. Endothelial dysfunction in pre-eclampsiaPharmacol. Rep.Year: 200658Suppl.697417332674
38. Furuya M.,Kurasawa K.,Nagahama K.,Kawachi K.,Nozawa A.,Takahashi T.,Aoki I.. Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsiaJ. PregnancyYear: 2011201112371721490787
39. Sunderland N.,Hennessy A.,Makris A.. Animal models of pre-eclampsiaAm. J. Reprod. Immunol.Year: 20116553354121134030
40. McCarthy F. P.,Kingdom J. C.,Kenny L. C.,Walsh S. K.. Animal models of preeclampsia; uses and limitationsPlacentaYear: 20113241341921497901
41. Kaaja R.,Laivuori H.,Laakso M.,Tikkanen M. J.,Ylikorkala O.. Evidence of a state of increased insulin resistance in preeclampsiaMetab. Clin. Exp.Year: 19994889289610421232
42. Scioscia M.,Gumaa K.,Rademacher T. W.. The link between insulin resistance and preeclampsia: new perspectivesJ. Reprod. Immunol.Year: 20098210010519628283
43. Vuguin P. M.. Animal models for small for gestational age and fetal programming of adult diseaseHorm. Res.Year: 20076811312317351325
44. Ogden E.,Hildebrand G. J.,Page E. W.. Rise of blood pressure during ischemia of the gravid uterusProc. Soc. Exp. Biol. Med.Year: 1940434951
45. Abitbol M. M.,Gallo G. R.,Pirani C. L.,Ober W. B.. Production of experimental toxemia in the pregnant rabbitAm. J. Obstet. Gynecol.Year: 19761244604701258901
46. Clark K. E.,Durnwald M.,Austin J. E.. A model for studying chronic reduction in uterine blood flow in pregnant sheepAm. J. Physiol.Year: 1982242H297H3017065164
47. Golden J. G.,Hughes H. C.,Lang C. M.. Experimental toxemia in the pregnant guinea pig (Cavia porcellus)Lab. Anim. Sci.Year: 1980301741797052372
48. Cavanagh D.,Rao P. S.,Tsai C. C.,O'Connor T. C.. Experimental toxemia in the pregnant primateAm. J. Obstet. Gynecol.Year: 19771287585403766
49. Abitbol M. M.,Pirani C. L.,Ober W. B.,Driscoll S. G.,Cohen M. W.. Production of experimental toxemia in the pregnant dogObstet. Gynecol.Year: 197648537548790242
50. Alexander B. T.,Kassab S. E.,Miller M. T.,Abram S. R.,Reckelhoff J. F.,Bennett W. A.,Granger J. P.. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxideHypertensionYear: 2001371191119511304523
51. Walsh S. K.,English F. A.,Johns E. J.,Kenny L. C.. Plasma-mediated vascular dysfunction in the reduced uterine perfusion pressure model of preeclampsiaHypertensionYear: 20095434535119564546
52. Crews J. K.,Herrington J. N.,Granger J. P.,Khalil R. A.. Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant ratHypertensionYear: 20003536737210642326
53. Gilbert J. S.,Babcock S. A.,Granger J. P.. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble Fms-like tyrosine kinase-1 expressionHypertensionYear: 2007501142114717923588
54. Payne J. A.,Alexander B. T.,Khalil R. A.. Reduced endothelial vascular relaxation in growth-restricted offspring of pregnant rats with reduced uterine perfusionHypertensionYear: 20034276877412874089
55. Anderson C. M.,Lopez F.,Sandeen A.,Johnson L.. Placental insufficiency: programming of leptin secretion, blood pressure, and postnatal growth in two generations of Sprague-Dawley ratsBiol. Res. Nurs.Year: 20091028429119017667
56. Heltemes A.,Gingery A.,Soldner E.L. B.,Bozadjieva N.,Jahr K. N.,Johnson B. K.,Gilbert J. S.. Chronic placental ischemia alters amniotic fluid milieu and results in impaired glucose tolerance, insulin resistance and hyperleptinemia in young ratsExp. Biol. Med.Year: 2010235892899
57. Wlodek M. E.,Westcott K.,Siebel A. L.,Owens J. A.,Moritz K. M.. Growth restriction before or after birth reduces nephron number and increases blood pressure in male ratsKidney Int.Year: 20087418719518432184
58. Alexander B. T.. Placental insufficiency leads to development of hypertension in growth-restricted offspringHypertensionYear: 20034145746212623943
59. Ojeda N. B.,Johnson W. R.,Dwyer T. M.,Alexander B. T.. Early renal denervation prevents development of hypertension in growth-restricted offspringClin. Exp. Pharmacol. Physiol.Year: 2007341212121617880379
60. Ojeda N. B.,Grigore D.,Robertson E. B.,Alexander B. T.. Estrogen protects against increased blood pressure in postpubertal female growth restricted offspringHypertensionYear: 20075067968517724277
61. Grigore D.,Ojeda N. B.,Robertson E. B.,Dawson A. S.,Huffman C. A.,Bourassa E. A.,Speth R. C.,Brosnihan K. B.,Alexander B. T.. Placental insufficiency results in temporal alterations in the renin angiotensin system in male hypertensive growth restricted offspringAm. J. Physiol. Regul. Integr. Comp. Physiol.Year: 2007293R804R81117537837
62. Alexander B. T.,Hendon A. E.,Ferril G.,Dwyer T. M.. Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusionHypertensionYear: 20054575475815699462
63. Mazzuca M. Q.,Wlodek M. E.,Dragomir N. M.,Parkington H. C.,Tare M.. Uteroplacental insufficiency programs regional vascular dysfunction and alters arterial stiffness in female offspringJ. Physiol.Year: 20105881997201020403978
64. Pascoe K. C.,Wlodek M. E.,Jones G. T.. Increased elastic tissue defect formation in the growth restricted brown Norway rat: a potential link between in utero condition and cardiovascular diseasePediatr. Res.Year: 20086412513018391838
65. Moritz K. M.,Mazzuca M. Q.,Siebel A. L.,Mibus A.,Arena D.,Tare M.,Owens J. A.,Wlodek M. E.. Uteroplacental insufficiency causes a nephron deficit, modest renal insufficiency but no hypertension with ageing in female ratsJ. Physiol.Year: 20095872635264619359373
66. Zamudio S.. The placenta at high altitudeHigh Alt. Med. Biol.Year: 2003417119112855050
67. Soleymanlou N.,Jurisica I.,Nevo O.,Ietta F.,Zhang X.,Zamudio S.,Post M.,Caniggia I.. Molecular evidence of placental hypoxia in preeclampsiaJ. Clin. Endocrinol. Metab.Year: 2005904299430815840747
68. Lai Z.,Kalkunte S.,Sharma S.. A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in miceHypertensionYear: 20115750551421263114
69. Morton J. S.,Rueda-Clausen C. F.,Davidge S. T.. Flow-mediated vasodilation is impaired in adult rat offspring exposed to prenatal hypoxiaJ. Appl. Physiol.Year: 20111101073108221233338
70. Williams S. J.,Hemmings D. G.,Mitchell J. M.,McMillen I. C.,Davidge S. T.. Effects of maternal hypoxia or nutrient restriction during pregnancy on endothelial function in adult male rat offspringJ. Physiol.Year: 200556512513515774515
71. Hemmings D. G.,Williams S. J.,Davidge S. T.. Increased myogenic tone in 7-month-old adult male but not female offspring from rat dams exposed to hypoxia during pregnancyAm. J. Physiol. Heart Circ. Physiol.Year: 2005289H674H68215833805
72. Peyronnet J.,Dalmaz Y.,Ehrström M.,Mamet J.,Roux J.-C.,Pequignot J.-M.,Thorén P.,Lagercrantz H.. Long-lasting adverse effects of prenatal hypoxia on developing autonomic nervous system and cardiovascular parameters in ratsPflügers Arch.Year: 2002443858865
73. Mutter W. P.,Karumanchi S. A.. Molecular mechanisms of preeclampsiaMicrovasc. Res.Year: 2008751817553534
74. Maynard S. E.,Min J.-Y.,Merchan J.,Lim K.-H.,Li J.,Mondal S.,Libermann T. A.,Morgan J. P.,Sellke F. W.,Stillman I. E.,et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJ. Clin. Invest.Year: 200311164965812618519
75. Ahmad S.,Ahmed A.. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsiaCirc. Res.Year: 20049588489115472115
76. Levine R. J.,Maynard S. E.,Qian C.,Lim K.-H.,England L. J.,Yu K. F.,Schisterman E. F.,Thadhani R.,Sachs B. P.,Epstein F. H.,et al. Circulating angiogenic factors and the risk of preeclampsiaN. Engl. J. Med.Year: 200435067268314764923
77. Lu F.,Longo M.,Tamayo E.,Maner W.,Al-Hendy A.,Anderson G. D.,Hankins G.D. V.,Saade G. R.. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant miceAm. J. Obstet. Gynecol.Year: 2007196396.e1396.e717403433
78. Lu F.,Bytautiene E.,Tamayo E.,Gamble P.,Anderson G. D.,Hankins G. D.,Longo M.,Saade G. R.. Gender-specific effect of overexpression of sFlt-1 in pregnant mice on fetal programming of blood pressure in the offspring later in lifeAm. J. Obstet. Gynecol.Year: 2007197418.e1418.e517904985
79. Maynard S.,Epstein F. H.,Karumanchi S. A.. Preeclampsia and angiogenic imbalanceAnnu. Rev. Med.Year: 200859617817937587
80. Huang P. L.,Huang Z.,Mashimo H.,Bloch K. D.,Moskowitz M. A.,Bevan J. A.,Fishman M. C.. Hypertension in mice lacking the gene for endothelial nitric oxide synthaseNatureYear: 19953772392427545787
81. Shesely E. G.,Gilbert C.,Granderson G.,Carretero C. D.,Carretero O. A.,Beierwaltes W. H.. Nitric oxide synthase gene knockout mice do not become hypertensive during pregnancyAm. J. Obstet. Gynecol.Year: 20011851198120311717657
82. Van Vliet B. N.,Chafe L. L.. Maternal endothelial nitric oxide synthase genotype influences offspring blood pressure and activity in miceHypertensionYear: 20074955656217261649
83. Mitchell G. F.,Conlin P. R.,Dunlap M. E.,Lacourcière Y.,Arnold J. M. O.,Ogilvie R. I.,Neutel J.,Izzo J. L.,Pfeffer M. A.. Aortic diameter, wall stiffness, and wave reflection in systolic hypertensionHypertensionYear: 20085110511118071054
84. Shirwany N. A.,Zou M.-h.. Arterial stiffness: a brief reviewActa Pharmacol. Sin.Year: 2010311267127620802505
85. Lewandowski A. J.,Lazdam M.,Davis E.,Kylintireas I.,Diesch J.,Francis J.,Neubauer S.,Singhal A.,Lucas A.,Kelly B.,Leeson P.. Short-term exposure to exogenous lipids in premature infants and long-term changes in aortic and cardiac functionArterioscler. Thromb. Vasc. Biol.Year: 2011312125213521817105
86. Briscoe T. A.,Rehn A. E.,Dieni S.,Duncan J. R.,Wlodek M. E.,Owens J. A.,Rees S. M.. Cardiovascular and renal disease in the adolescent guinea pig after chronic placental insufficiencyAm. J. Obstet. Gynecol.Year: 200419184785515467552
87. Herrera E. A.,Camm E. J.,Cross C. M.,Mullender J. L.,Wooding F. B.,Giussani D. A.. Morphological and functional alterations in the aorta of the chronically hypoxic fetal ratJ. Vasc. Res.Year: 201149505821985843
88. Camm E. J.,Hansell J. A.,Kane A. D.,Herrera E. A.,Lewis C.,Wong S.,Morrell N. W.,Giussani D. A.. Partial contributions of developmental hypoxia and undernutrition to prenatal alterations in somatic growth and cardiovascular structure and functionAm. J. Obstet. Gynecol.Year: 2010203495.e24495.e3420708165
89. Wang Z.,Huang Z.,Lu G.,Lin L.,Ferrari M.. Hypoxia during pregnancy in rats leads to early morphological changes of atherosclerosis in adult offspringAm. J. Physiol. Heart Circ. Physiol.Year: 2009296H1321H132819304947
90. Urbina E. M.,Williams R. V.,Alpert B. S.,Collins R. T.,Daniels S. R.,Hayman L.,Jacobson M.,Mahoney L.,Mietus-Snyder M.,Rocchini A.,et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart AssociationHypertensionYear: 20095491995019729599
91. Lorenz M. W.,Markus H. S.,Bots M. L.,Rosvall M.,Sitzer M.. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysisCirculationYear: 200711545946717242284
92. Akcakus M.,Altunay L.,Yikilmaz A.,Yazici C.,Koklu E.. The relationship between abdominal aortic intima-media thickness and lipid profile in neonates born to mothers with preeclampsiaJ. Pediatr. Endocrinol. Metab.Year: 2010231143114921284327
93. Aeschbacher B. C.,Hutter D.,Fuhrer J.,Weidmann P.,Delacretaz E.,Allemann Y.. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertensionAm. J. Hypertens.Year: 20011410611311243300
94. Rueda-Clausen C. F.,Morton J. S.,Lopaschuk G. D.,Davidge S. T.. Long-term effects of intrauterine growth restriction on cardiac metabolism and susceptibility to ischaemia/reperfusionCardiovasc. Res.Year: 20119028529421097804
95. Rueda-Clausen C. F.,Morton J. S.,Davidge S. T.. Effects of hypoxia-induced intrauterine growth restriction on cardiopulmonary structure and function during adulthoodCardiovasc. Res.Year: 20098171372219088083
96. Tong W.,Xue Q.,Li Y.,Zhang L.. Maternal hypoxia alters matrix metalloproteinase expression patterns and causes cardiac remodeling in fetal and neonatal ratsAm. J. Physiol. Heart Circ. Physiol.Year: 2011301H2113H212221856922
97. Ream M.,Ray A. M.,Chandra R.,Chikaraishi D. M.. Early fetal hypoxia leads to growth restriction and myocardial thinningAm. J. Physiol. Regul. Integr. Comp. Physiol.Year: 2008295R583R59518509101
98. Bae S.,Xiao Y.,Li G.,Casiano C. A.,Zhang L.. Effect of maternal chronic hypoxic exposure during gestation on apoptosis in fetal rat heartAm. J. Physiol. Heart Circ. Physiol.Year: 2003285H983H99012750058
99. Li G.,Xiao Y.,Estrella J. L.,Ducsay C. A.,Gilbert R. D.,Zhang L.. Effect of fetal hypoxia on heart susceptibility to ischemia and reperfusion injury in the adult ratJ. Soc. Gynecol. Investig.Year: 200310265274
100. Xu Y.,Williams S. J.,O'Brien D.,Davidge S. T.. Hypoxia or nutrient restriction during pregnancy in rats leads to progressive cardiac remodeling and impairs postischemic recovery in adult male offspringFASEB J.Year: 2006201251125316632594
101. Patterson A. J.,Chen M.,Xue Q.,Xiao D.,Zhang L.. Chronic prenatal hypoxia induces epigenetic programming of PKCϵ gene repression in rat hearts: novelty and significanceCirc. Res.Year: 201010736537320538683
102. Budas G. R.,Mochly-Rosen D.. Mitochondrial protein kinase Cϵ (PKCϵ): emerging role in cardiac protection from ischaemic damageBiochem. Soc. Trans.Year: 2007351052105417956277
103. Enquobahrie D. A.,Abetew D. F.,Sorensen T. K.,Willoughby D.,Chidambaram K.,Williams M. A.. Placental microRNA expression in pregnancies complicated by preeclampsiaAm. J. Obstet. Gynecol.Year: 2011204178.e12178.e2121093846
104. Himmelmann A.,Svensson A.,Hansson L.. Five-year follow-up of blood pressure and left ventricular mass in children with different maternal histories of hypertension: the Hypertension in Pregnancy Offspring StudyJ. Hypertens.Year: 19941289958157950
105. Fugelseth D.,Ramstad H. B.,Kvehaugen A. S.,Nestaas E.,Støylen A.,Staff A. C.. Myocardial function in offspring 5–8 years after pregnancy complicated by preeclampsiaEarly Hum. Dev.Year: 20118753153521550734
106. Hadi H. A.,Carr C. S.,Al Suwaidi J.. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcomeVasc. Health Risk Manag.Year: 2005118319817319104
107. Halcox J.P. J.,Donald A. E.,Ellins E.,Witte D. R.,Shipley M. J.,Brunner E. J.,Marmot M. G.,Deanfield J. E.. Endothelial function predicts progression of carotid intima-media thicknessCirculationYear: 20091191005101219204308
108. Luscher T. F.. The endothelium and cardiovascular disease: a complex relationN. Engl. J. Med.Year: 1994330108110838127338
109. Lazdam M.,Lewandowski A. J.,Kylintireas I.,Cunnington C.,Diesch J.,Francis J.,Trevitt C.,Neubauer S.,Singhal A.,Leeson P.. Impaired endothelial responses in apparently healthy young people associated with subclinical variation in blood pressure and cardiovascular phenotypeAm. J. Hypertens.Year: 201225465321976278
110. Payne J. A.,Alexander B. T.,Khalil R. A.. Decreased endothelium-dependent NO-cGMP vascular relaxation and hypertension in growth-restricted rats on a high-salt dietHypertensionYear: 20044342042714707161
111. Lu F.,Goharkhay N.,Bytautiene E.,Tamayo E.,Orise P.,Anderson G. D.,Longo M.,Saade G. R.. Fetal programming of adult vascular function in a preeclampsia-like animal model is gender-specificAm. J. Obstet. Gynecol.Year: 2007197S141S141
112. Chiossi G.,Costantine M. M.,Tamayo E. H.,Orise P.,Hankins G. D. V.,Saade G. R.,Longo M.. Effect of age and gender on the progression of adult vascular dysfunction in a mouse model of fetal programming lacking endothelial nitric oxide synthaseAm. J. Physiol. Heart Circ. Physiol.Year: 2011301H297H30521572009
113. Longo M.,Jain V.,Vedernikov Y. P.,Bukowski R.,Garfield R. E.,Hankins G. D.,Anderson G. D.,Saade G. R.. Fetal origins of adult vascular dysfunction in mice lacking endothelial nitric oxide synthaseAm. J. Physiol. Regul. Integr. Comp. Physiol.Year: 2005288R1114R112115626780
114. Kvehaugen A. S.,Dechend R.,Ramstad H. B.,Troisi R.,Fugelseth D.,Staff A. C.. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsiaHypertensionYear: 201158636921606387
115. Touwslager R. N.,Houben A. J.,Gielen M.,Zeegers M. P.,Stehouwer C. D.,Zimmermann L. J.,Kessels A. G.,Gerver W. J.,Blanco C. E.,Mulder A. L.. Endothelial vasodilatation in newborns is related to body size and maternal hypertensionJ. Hypertens.Year: 20123012413122045125
116. Davidge S. T.,Signorella A. P.,Lykins D. L.,Gilmour C. H.,Roberts J. M.. Evidence of endothelial activation and endothelial activators in cord blood of infants of preeclamptic womenAm. J. Obstet. Gynecol.Year: 1996175130113068942505
117. Morton J. S.,Rueda-Clausen C. F.,Davidge S. T.. Mechanisms of endothelium-dependent vasodilation in male and female, young and aged offspring born growth restrictedAm. J. Physiol. Regul. Integr. Comp. Physiol.Year: 2010298R930R93820053962
118. Moyes A. J.,Maldonado-Perez D.,Gray G. A.,Denison F. C.. Enhanced angiogenic capacity of human umbilical vein endothelial cells from women with preeclampsiaReprod. Sci.Year: 20111837438220962332
119. Staff A. C.,Braekke K.,Harsem N. K.,Lyberg T.,Holthe M. R.. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsiaEur. J. Obstet. Gynecol. Reprod. Biol.Year: 2005122333915935542
120. Tsao P.-N.,Wei S.-C.,Su Y.-N.,Chou H.-C.,Chen C.-Y.,Hsieh W.-S.. Excess soluble fms-like tyrosine kinase 1 and low platelet counts in premature neonates of preeclamptic mothersPediatricsYear: 200511646847216061605
121. Orbak Z.,Zor N.,Energin V. M.,Selimoğlu M. A.,ALP H.,Akçay F.. Endothelin-1 levels in mothers with eclampsia-pre-eclampsia and their newbornsJ. Trop. Pediatr.Year: 19984447499538607
122. Wang Y.,Zhou Y.,He L.,Hong K.,Su H.,Wu Y.,Wu Q.,Han M.,Cheng X.. Gene delivery of soluble vascular endothelial growth factor receptor-1 (sFlt-1) inhibits intra-plaque angiogenesis and suppresses development of atherosclerotic plaqueClin. Exp. Med.Year: 20111111312120821246
123. Heazell A. E.,Brown M.,Worton S. A.,Dunn W. B.. The effects of oxygen on normal and pre-eclamptic placental tissue–insights from metabolomicsPlacentaYear: 201132Suppl. 2S119S12421195475
124. Libby G.,Murphy D.,McEwan N.,Greene S.,Forsyth J.,Chien P.,Morris A.. Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study from the Walker cohortDiabetologiaYear: 20075052353017187247
125. Akcakus M.,Koklu E.,Baykan A.,Yikilmaz A.,Coskun A.,Gunes T.,Kurtoglu S.,Narin N.. Macrosomic newborns of diabetic mothers are associated with increased aortic intima-media thickness and lipid concentrationsHorm. Res.Year: 20076727728317191031
126. Catarino C.,Rebelo I.,Belo L.,Rocha-Pereira P.,Rocha S.,Bayer Castro E.,Patrício B.,Quintanilha A.,Santos-Silva A.. Fetal lipoprotein changes in pre-eclampsiaActa Obstetr. Gynecol. Scand.Year: 200887628634
127. Howlader M. Z.,Parveen S.,Tamanna S.,Khan T. A.,Begum F.. Oxidative stress and antioxidant status in neonates born to pre-eclamptic motherJ. Trop. Pediatr.Year: 20095536336719380372
128. Ophir E.,Dourleshter G.,Hirsh Y.,Fait V.,German L.,Bornstein J.. Newborns of pre-eclamptic women: a biochemical difference present in uteroActa Obstet. Gynecol. Scand.Year: 2006851172117817068675
129. Rodie V. A.,Caslake M. J.,Stewart F.,Sattar N.,Ramsay J. E.,Greer I. A.,Freeman D. J.. Fetal cord plasma lipoprotein status in uncomplicated human pregnancies and in pregnancies complicated by pre-eclampsia and intrauterine growth restrictionAtherosclerosisYear: 200417618118715306192
130. Yavuz T.,Yavuz O.,Ozdemir I.,Afsar Y.. Cord blood lipoprotein profile after magnesium sulphate treatment in pre-eclamptic patientsActa Paediatr.Year: 2006951224122716982494
131. Rueda-Clausen C. F.,Dolinsky V. W.,Morton J. S.,Proctor S. D.,Dyck J. R. B.,Davidge S. T.. Hypoxia-induced intrauterine growth restriction increases the susceptibility of rats to high-fat diet-induced metabolic syndromeDiabetesYear: 20116050751621270262
132. Medica I.,Kastrin A.,Peterlin B.. Genetic polymorphisms in vasoactive genes and preeclampsia: a meta-analysisEur. J. Obstet. Gynecol. Reprod. Biol.Year: 200713111512617112651
133. Yu C. K.,Casas J. P.,Savvidou M. D.,Sahemey M. K.,Nicolaides K. H.,Hingorani A. D.. Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) and development of pre-eclampsia: a case-control study and a meta-analysisBMC Pregnancy ChildbirthYear: 20066716542455
134. Odom L. N.,Taylor H. S.. Environmental induction of the fetal epigenomeExpert Rev. Obstet. Gynecol.Year: 2010565766421297874
135. Yuen R. K. C.,Penaherrera M. S.,von Dadelszen P.,McFadden D. E.,Robinson W. P.. DNA methylation profiling of human placentas reveals promoter hypomethylation of multiple genes in early-onset preeclampsiaEur. J. Hum. Genet.Year: 2010181006101220442742
136. Gao W.-l.,Li D.,Xiao Z.-x.,Liao Q.-p.,Yang H.-x.,Li Y.-x.,Ji L.,Wang Y.-l.. Detection of global DNA methylation and paternally imprinted H19 gene methylation in preeclamptic placentasHypertens. Res.Year: 20113465566121326306
137. Yu L.,Chen M.,Zhao D.,Yi P.,Lu L.,Han J.,Zheng X.,Zhou Y.,Li L.. The H19 gene imprinting in normal pregnancy and pre-eclampsiaPlacentaYear: 20093044344719342096
138. Bannister A. J.,Kouzarides T.. Reversing histone methylationNatureYear: 20054361103110616121170
139. Weaver I. C. G.,Champagne F. A.,Brown S. E.,Dymov S.,Sharma S.,Meaney M. J.,Szyf M.. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in lifeJ. Neurosci.Year: 200525110451105416306417
140. Lewandowski A. J.,Davis E. F.,Lazdam M.,Leeson P.. From gene to epigene-based therapies targeting the vascular endotheliumCurr. Vasc. Pharmacol.Year: 20112121
141. Anderson C. M.,Lopez F.,Zimmer A.,Benoit J. N.. Placental insufficiency leads to developmental hypertension and mesenteric artery dysfunction in two generations of Sprague-Dawley rat offspringBiol. Reprod.Year: 20067453854416306423
142. Shirodkar A. V.,Marsden P. A.. Epigenetics in cardiovascular diseaseCurr. Opin. Cardiol.Year: 20112620921521415727
143. Rahman I.,Marwick J.,Kirkham P.. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-κB and pro-inflammatory gene expressionBiochem. Pharmacol.Year: 2004681255126715313424
144. von Zglinicki T.. Oxidative stress shortens telomeresTrends Biochem. Sci.Year: 20022733934412114022
145. Dennery P. A.. Oxidative stress in development: Nature or nurture?Free Radical Biol. Med.Year: 2010491147115120656021
146. Arikan S.,Konukoglu D.,Arikan C.,Akcay T.,Davas I.. Lipid peroxidation and antioxidant status in maternal and cord bloodGynecol. Obstet. Invest.Year: 20015114514911306898
147. Erdem M.,Harma M.,Harma I.,Arikan I.,Barut A.. Comparative study of oxidative stress in maternal blood with that of cord blood and maternal milkArch. Gynecol. Obstet.Year: 20122851521431841
148. Fujimaki A.,Watanabe K.,Mori T.,Kimura C.,Shinohara K.,Wakatsuki A.. Placental oxidative DNA damage and its repair in preeclamptic women with fetal growth restrictionPlacentaYear: 20113236737221435716
149. Davis J. M.,Auten R. L.. Maturation of the antioxidant system and the effects on preterm birthSemin. Fetal Neonatal Med.Year: 20101519119520452845
150. Illsinger S.,Janzen N.,Sander S.,Schmidt K. H.,Bednarczyk J.,Mallunat L.,Bode J.,Hagebolling F.,Hoy L.,Lucke T.,et al. Preeclampsia and HELLP syndrome: impaired mitochondrial function in umbilical endothelial cellsReprod. Sci.Year: 20101721922620065299
151. Hart E.,Charkoudian N.. Sympathetic neural mechanisms in human blood pressure regulationCurr. Hypertens. Rep.Year: 20111323724321293977
152. Thayer J. F.,Yamamoto S. S.,Brosschot J. F.. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factorsInt. J. Cardiol.Year: 201014112213119910061
153. Phillips D. I. W.,Jones A.,Goulden P. A.. Birth weight, stress, and the metabolic syndrome in adult lifeAnn. N.Y. Acad. Sci.Year: 20061083283617148731
154. Tenhola S.,Rahiala E.,Halonen P.,Vanninen E.,Voutilainen R.. Maternal preeclampsia predicts elevated blood pressure in 12-year-old children: evaluation by ambulatory blood pressure monitoringPediatr. Res.Year: 20065932032416439600
155. Salinas C. E.,Villena M.,Blanco C. E.,Giussani D. A.. Adrenocortical suppression in highland chick embryos is restored during incubation at sea levelHigh Alt. Med. Biol.Year: 201112798721452969
156. Myers D. A.,Hyatt K.,Mlynarczyk M.,Bird I. M.,Ducsay C. A.. Long-term hypoxia represses the expression of key genes regulating cortisol biosynthesis in the near-term ovine fetusAm. J. Physiol. Regul. Integr. Comp. Physiol.Year: 2005289R1707R171416099825
157. Monau T. R.,Vargas V. E.,King N.,Yellon S. M.,Myers D. A.,Ducsay C. A.. Long-term hypoxia increases endothelial nitric oxide synthase expression in the ovine fetal adrenalReprod. Sci.Year: 20091686587419525401
158. Raff H.,Bruder E.,Jankowski B.,Engeland W.. The effect of fetal hypoxia on adrenocortical function in the 7-day-old ratEndocrineYear: 20001311111611051054
159. Wlodek M. E.,Mibus A.,Tan A.,Siebel A. L.,Owens J. A.,Moritz K. M.. Normal lactational environment restores nephron endowment and prevents hypertension after placental restriction in the ratJ. Am. Soc. Nephrol.Year: 2007181688169617442788
160. Baserga M.,Hale M. A.,Wang Z. M.,Yu X.,Callaway C. W.,McKnight R. A.,Lane R. H.. Uteroplacental insufficiency alters nephrogenesis and downregulates cyclooxygenase-2 expression in a model of IUGR with adult-onset hypertensionAm. J. Physiol. Regul. Integr. Comp. Physiol.Year: 2007292R1943R195517272666
161. Baserga M.,Bares A. L.,Hale M. A.,Callaway C. W.,McKnight R. A.,Lane P. H.,Lane R. H.. Uteroplacental insufficiency affects kidney VEGF expression in a model of IUGR with compensatory glomerular hypertrophy and hypertensionEarly Hum. Dev.Year: 20098536136719188030
162. Ojeda N. B.,Grigore D.,Yanes L. L.,Iliescu R.,Robertson E. B.,Zhang H.,Alexander B. T.. Testosterone contributes to marked elevations in mean arterial pressure in adult male intrauterine growth restricted offspringAm. J. Physiol. Regul. Integr. Comp. Physiol.Year: 2007292R758R76316917022
163. Weir M. R.. Hypertension and the kidney: perspectives on the relationship of kidney disease and cardiovascular diseaseClin. J. Am. Soc. Nephrol.Year: 200942045205019608710
164. Johansson A.,Curran J. E.,Johnson M. P.,Freed K. A.,Fenstad M. H.,Bjorge L.,Eide I. P.,Carless M. A.,Rainwater D. L.,Goring H. H. H.,et al. Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular diseaseEur. J. Hum. Genet.Year: 20111979680021343950
165. Geddes K.,Magalhaes J. G.,Girardin S. E.. Unleashing the therapeutic potential of NOD-like receptorsNat. Rev. Drug DiscoveryYear: 20098465479
166. Friedmann E.,Hauben E.,Maylandt K.,Schleeger S.,Vreugde S.,Lichtenthaler S. F.,Kuhn P.-H.,Stauffer D.,Rovelli G.,Martoglio B.. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFα in activated dendritic cells to trigger IL-12 productionNat. Cell Biol.Year: 2006884384816829952
167. Duckitt K.,Harrington D.. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studiesBMJYear: 200533056515743856
168. Zenclussen A. C.,Fest S.,Joachim R.,Klapp B. F.,Arck P. C.. Introducing a mouse model for pre-eclampsia: adoptive transfer of activated Th1 cells leads to pre-eclampsia-like symptoms exclusively in pregnant miceEur. J. Immunol.Year: 20043437738714768042
169. LaMarca B. B. D.,Bennett W. A.,Alexander B. T.,Cockrell K.,Granger J. P.. Hypertension produced by reductions in uterine perfusion in the pregnant ratHypertensionYear: 2005461022102516144982
170. LaMarca B. B. D.,Cockrell K.,Sullivan E.,Bennett W.,Granger J. P.. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant ratsHypertensionYear: 200546828615928030
171. Hansson G. K.,Hermansson A.. The immune system in atherosclerosisNat. Immunol.Year: 20111220421221321594
172. Roifman I.,Beck P. L.,Anderson T. J.,Eisenberg M. J.,Genest J.. Chronic inflammatory diseases and cardiovascular risk: a systematic reviewCan. J. Cardiol.Year: 20112717418221459266
173. Laskowska M.,Laskowska K.,Leszczyńska-Gorzelak B.,Oleszczuk J.. Comparative analysis of the maternal and umbilical interleukin-8 levels in normal pregnancies and in pregnancies complicated by preeclampsia with intrauterine normal growth and intrauterine growth retardationJ. Matern.-Fetal Neonat. Med.Year: 200720527532
174. Bujold E.,Chaiworapongsa T.,Romero R.,Gervasi M. T.,Espinoza J.,Goncalves L. F.,Berman S.,Yoon B. H.,Kim Y. M.. Neonates born to pre-eclamptic mothers have a higher percentage of natural killer cells (CD3/CD56+16+) in umbilical cord blood than those without pre-eclampsiaJ. Matern.-Fetal Neonat. Med.Year: 200314305312
175. Kuntz T. B.,Christensen R. D.,Stegner J.,Duff A.,Patrick A.,Koenig J. M.. Fas and Fas ligand expression in maternal blood and in umbilical cord blood in preeclampsiaPediatr. Res.Year: 20015074374911726734
176. Baker D. A.,Hameed C.,Tejani N.,Thomas J.,Dattwyler R.. Lymphocyte subsets in the neonates of preeclamptic mothersAm. J. Reprod. Immunol. Microbiol.Year: 1987141071092963550
177. Langford H.,Watson R.. Prepregnant blood pressure, hypertension during pregnancy, and later blood pressure of mothers and offspringHypertensionYear: 198021301337399645
178. Palti H.,Rothschild E.. Blood pressure and growth at 6 years of age among offsprings of mothers with hypertension of pregnancyEarly Hum. Dev.Year: 1989192632692806155
179. Higgins M.,Keller J.,Moore F.,Ostrander L.,Metzner H.,Stock L.. Studies of blood pressure in Tecumseh, Michigan. I. Blood pressure in young people and its relationship to personal and familial characteristics and complications of pregnancy in mothersAm. J. Epidemiol.Year: 19801111421556965561
180. Schreuder M. F.,van Wijk J. A.,Delemarre-van de Waal H. A.. Intrauterine growth restriction increases blood pressure and central pulse pressure measured with telemetry in aging ratsJ. Hypertens.Year: 2006241337134316794483
181. Bytautiene E.,Tamayo E.,Kechichian T.,Drever N.,Gamble P.,Hankins G. D. V.,Saade G. R.. Prepregnancy obesity and sFlt1-induced preeclampsia in mice: developmental programming model of metabolic syndromeAm. J. Obstet. Gynecol.Year: 2011204398.e1398.e821444063
182. Costantine M. M.,Ghulmiyyah L. M.,Tamayo E.,Hankins G. D. V.,Saade G. R.,Longo M.. Transgenerational effect of fetal programming on vascular phenotype and reactivity in endothelial nitric oxide synthase knockout mouse modelAm. J. Obstet. Gynecol.Year: 2008199250.e1250.e718771972
183. Miller F. C.,Read J. A.,Cabal L.,Siassi B.. Heart rate and blood pressure in infants of pre-eclamptic mothers during the first hour of lifeCrit. Care Med.Year: 1983115325356861501
184. Kvehaugen A. S.,Andersen L. F.,Staff A. C.. Anthropometry and cardiovascular risk factors in women and offspring after pregnancies complicated by preeclampsia or diabetes mellitusActa Obstet. Gynecol. Scand.Year: 2010891478148520955102
185. Hiller J. E.,Crowther C. A.,Moore V. A.,Willson K.,Robinson J. S.. Calcium supplementation in pregnancy and its impact on blood pressure in children and women: follow up of a randomised controlled trialAust. N.Z. J. Obstet. Gynaecol.Year: 20074711512117355300
186. Longo M.,Jain V.,Langenveld J.,Vedernikov Y. P.,Garfield R. E.,Hankins G. D. V.,Anderson G. D.,Saade G. R.. Enhanced growth and improved vascular function in offspring from successive pregnancies in endothelial nitric oxide synthase knockout miceAm. J. Obstet. Gynecol.Year: 20041911470147615507985
187. Veas C. J.,Aguilera V. C.,Munoz I. J.,Gallardo V. I.,Miguel P. L.,Gonzalez M. A.,Lamperti L. I.,Escudero C. A.,Aguayo C. R.. Fetal endothelium dysfunction is associated with circulating maternal levels of sE-selectin, sVCAM1, and sFlt-1 during pre-eclampsiaJ. Matern.-Fetal Neonatal. Med.Year: 2011241371137721381877
188. Byers B. D.,Betancourt A.,Lu F.,Hankins G. D. V.,Longo M.,Saade G. R.,Bytautiene E.. The effect of prepregnancy obesity and sFlt-1-induced preeclampsia-like syndrome on fetal programming of adult vascular function in a mouse modelAm. J. Obstet. Gynecol.Year: 2009200432.e1432.e719318153
189. Cetinkaya M.,Bostan O.,Koksal N.,Semizel E.,Ozkan H.,Cakir S.. Early left ventricular diastolic dysfunction in premature infants born to preeclamptic mothersJ. Perinat. Med.Year: 201139899521142411
190. Xue Q.,Dasgupta C.,Chen M.,Zhang L.. Foetal hypoxia increases cardiac AT2R expression and subsequent vulnerability to adult ischaemic injuryCardiovasc. Res.Year: 20118930030820870653
191. Ghulmiyyah L. M.,Costantine M. M.,Yin H.,Tamayo E.,Clark S. M.,Hankins G. D. V.,Saade G. R.,Longo M.. The role of oxidative stress in the developmental origin of adult hypertensionAm. J. Obstet. Gynecol.Year: 2011205155.e7155.e1121531372
192. Engelbregt M. J.,van Weissenbruch M. M.,Popp-Snijders C.,Lips P.,Delemarre-van de Waal H. A.. Body mass index, body composition, and leptin at onset of puberty in male and female rats after intrauterine growth retardation and after early postnatal food restrictionPediatr. Res.Year: 20015047447811568290
193. Ojeda N. B.,Royals T. P.,Black J. T.,Dasinger J. H.,Johnson J. M.,Alexander B. T.. Enhanced sensitivity to acute angiotensin II is testosterone dependent in adult male growth-restricted offspringAm. J. Physiol. Regul. Integr. Comp. Physiol.Year: 2010298R1421R142720219873
194. Simmons R. A.,Templeton L. J.,Gertz S. J.. Intrauterine growth retardation leads to the development of Type 2 diabetes in the ratDiabetesYear: 2001502279228611574409
195. Nüsken K.-D.,Dötsch J.,Rauh M.,Rascher W.,Schneider H.. Uteroplacental insufficiency after bilateral uterine artery ligation in the rat: impact on postnatal glucose and lipid metabolism and evidence for metabolic programming of the offspring by sham operationEndocrinologyYear: 20081491056106318063678
196. Camm E. J.,Martin-Gronert M. S.,Wright N. L.,Hansell J. A.,Ozanne S. E.,Giussani D. A.. Prenatal hypoxia independent of undernutrition promotes molecular markers of insulin resistance in adult offspringFASEB J.Year: 20112542042720923964
197. Styrud J.,Eriksson U. J.,Grill V.,Swenne I.. Experimental intrauterine growth retardation in the rat causes a reduction of pancreatic β-cell mass, which persists into adulthoodBiol. NeonateYear: 20058812212815942163
198. Goland R. S.,Tropper P. J.,Warren W. B.,Stark R. I.,Jozak S. M.,Conwell I. M.. Concentrations of corticotrophin-releasing hormone in the umbilical-cord blood of pregnancies complicated by pre-eclampsiaReprod. Fertil. Dev.Year: 19957122712308848592
199. Laatikainen T.,Virtanen T.,Kaaja R.,Salminen-Lappalainen K.. Corticotropin-releasing hormone in maternal and cord plasma in pre-eclampsiaEur. J. Obstet. Gynecol. Reprod. Biol.Year: 19913919241851489
200. Jansson T.,Lambert G. W.. Effect of intrauterine growth restriction on blood pressure, glucose tolerance and sympathetic nervous system activity in the rat at 3–4 months of ageJ. Hypertens.Year: 1999171239124810489100
201. Sitras V.,Paulssen R. H.,Grønaas H.,Leirvik J.,Hanssen T. A.,Vårtun Å.,Acharya G.. Differential placental gene expression in severe preeclampsiaPlacentaYear: 20093042443319249095
202. Zhu X.-m.,Han T.,Sargent I. L.,Yin G.-w.,Yao Y.-q.. Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnanciesAm. J. Obstet. Gynecol.Year: 2009200661.e1661.e719285651
203. Hoegh A. M.,Borup R.,Nielsen F. C.,Sorensen S.,Hviid T. V.. Gene expression profiling of placentas affected by pre-eclampsiaJ. Biomed. Biotechnol.Year: 2010201078754520204130
204. Centlow M.,Wingren C.,Borrebaeck C.,Brownstein M. J.,Hansson S. R.. Differential gene expression analysis of placentas with increased vascular resistance and pre-eclampsia using whole-genome microarraysJ. PregnancyYear: 2011201147235421490790
205. Loset M.,Mundal S. B.,Johnson M. P.,Fenstad M. H.,Freed K. A.,Lian I. A.,Eide I. P.,Bjorge L.,Blangero J.,Moses E. K.,Austgulen R.. A transcriptional profile of the decidua in preeclampsiaAm. J. Obstet. Gynecol.Year: 201120484.e184.e2720934677
206. Várkonyi T.,Nagy B.,Füle T.,Tarca A. L.,Karászi K.,Schönléber J.,Hupuczi P.,Mihalik N.,Kovalszky I.,Rigó J. Jr,et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similarPlacentaYear: 201132Suppl. 1S21S2920541258
207. Ozturk E.,Balat O.,Acılmıs Y. G.,Ozcan C.,Pence S.,Erel Ö.. Measurement of the placental total antioxidant status in preeclamptic women using a novel automated methodJ. Obstet. Gynaecol. Res.Year: 20113733734221314804
208. McElrath T. F.,Fichorova R. N.,Allred E. N.,Hecht J. L.,Ismail M. A.,Yuan H.,Leviton A.. Blood protein profiles of infants born before 28 weeks differ by pregnancy complicationAm. J. Obstet. Gynecol.Year: 2011204418.e1e418.e1221349490


[Figure ID: F1]
Figure 1  Potential mechanism of cardiovascular programming in the offspring following a pre-eclamptic pregnancy

Summary of the potential and demonstrated mechanisms by which in utero exposure to pre-eclampsia may lead to altered cardiovascular physiology and risk in the offspring in later life.

[Figure ID: F2]
Figure 2  Timing of the reduction in uterine artery perfusion and offspring BP

Summary of the results of studies (reference number given) considering the effect of RUPP at different points of gestation on offspring BP. Continuous lines indicate that studies have demonstrated an increase in BP in RUPP animals compared with controls at this time point, whereas broken lines indicate no difference in BP compared with controls. The colour of the lines indicates the timing of the in utero insult; the red line showing the result of studies in which uterine artery perfusion was reduced at day (D) 14, the blue line at day 18 and the green line at day 19 of gestation. This suggest that the timing of the insult may be critical in determining the effect on offspring BP. Studies of mid-gestation (14 days of gestation) reduction in uterine artery flow have demonstrated relatively consistent increases in BP from early life (4 weeks of age). Interventions later in gestation (days 18 and 19 of gestation) have not indicated consistent increases in early life, although some studies have indicated later development of hypertension which may be linked to dietary factors.

[Figure ID: F3]
Figure 3  Cardiovascular changes associated with in utero exposure to hypoxia

The major findings from studies (reference number given) considering the effects of pre-natal chronic hypoxia at different points of gestation on offspring cardiovascular physiology are outlined. The colour of the lines indicates the timing of commencement of in utero hypoxia; The dark blue line indicates hypoxia for the entire period of gestation, the green line from day 5, the red line from day 6, the purple line from day 7, the orange line from day 15, and the pale blue line from day 18 of gestation. The percentage of oxygen used in each study is indicated above the lines. Studies have been divided into those where hypoxia was commenced in early pregnancy (before day 10 in rat models or from conception in other animals) and those where hypoxia was commenced later in pregnancy. Studies later in pregnancy have demonstrated vascular, cardiac and metabolic alterations in the offspring. Fewer studies have considered the effects of early-onset hypoxia, but these have demonstrated similar findings in terms of the vascular phenotype.

[Figure ID: F4]
Figure 4  Effect of maternal systemic endothelial dysfunction during pregnancy on offspring BP

Experiments in eNOS-knockout mice have demonstrated the importance of the development in an environment of maternal systemic endothelial dysfunction. eNOS-knockout heterozygotes born to knockout mothers have shown some evidence of increased BP and BP variability compared with heterozygotes gestated in an environment with normal endothelial function. Second-generation offspring also show alterations in BP. Maternal systemic endothelial dysfunction during pregnancy is characteristic of the human syndrome of pre-eclampsia and these models highlight the potential importance of this in utero insult on later offspring vascular function [82].

[TableWrap ID: T1] Table 1  Evidence of cardiovascular programming following pre-eclampsia

An overview of some of the evidence for cardiovascular programming in offspring of animal models and humans born to pre-eclamptic mothers. Positive findings are underlined in roman and negative findings are indicated in italic.

Human offspring
Animal model offspring Perinatal Later life
Parameter RUPP Hypoxia sFLT1 eNOS Placenta Cord blood HUVECs Neonate Childhood Adolescence Young adult
 ↑BP [6365][5458,6062,159,160,162,180] [72,100] [78,181] [82,182] [183] [114,184][10,15,177,178,185] [11][7,8,13,14] [12]
 Altered BP under stress [72] [82]
Vascular structural changes
 ↑IMT/vascular wall thickness [63,64,86] [8789] [92] [12]
 ↑Arterial stiffness [55,63] [69] [186][113] [15] [12]
Vascular functional changes
 Endothelial dysfunction [63,141][54,110] [6971] [112,113,182,186] [116] [187] [31] [15] [11] [12]
 Non-endothelial function [110,141] [71] [188] [113,182] [11] [12]
Cardiac structural and functional changes
 Altered cardiac structure [65][57,86] [72,9598] [181] [105]
 LV dysfunction [95] [189] [105]
 ↑IR injury [94,99101,190]
Renal structural and functional changes
 Altered structure and function [59,62,65][57,58,61,64,65,86,159161] [191]
Metabolic changes
 ↑BMI [54,5659,62,65,86, 110,180,192,193][194,195] [71,72,88,94,95, 100,131,196] [77,181,188] [82,113] [92] [178,184][7,8,10,15] [11,14][16] [12][13]
 ↑Serum lipids [56,63,195] [196] [181] [92,126130] [15] [14] [12]
[131] [114]
 Altered glucose metabolism [63][56,194,195,197] [196] [181] [14] [12]
Altered sympatho-adrenal function
 Adrenal hormones [62,161,195] [72,155,157] [198,199] [154]
 Sympathetic changes [200] [72,158]
Genetic/epigenetic changes
 Gene expression [57,61,65,160,161][62,63,159] [96,97,100,131,190,196] [191] [67,103,164,201206]
 Epigenetics [101] [135137]
 ↓Antioxidants [207] [127,147]
 ↑Oxidative stress [56] [148] [127,147,148]
 ↑Anti-angiogenic factors [120,121] [114]
 ↑PlGF/VEGF [120] [114]
 Altered inflammation [63] [131] [181] [173176] [208] [15,114]

Article Categories:
  • Review Article
Article Categories:
  • S1
Article Categories:
  • S9

Keywords: blood pressure, cardiovascular disease, in utero, offspring, pre-eclampsia, pregnancy, vascular function.
Keywords: BP, blood pressure, BMI, body mass index, CYP, cytochrome P450, eNOS, endothelial NO synthase, HUVEC, human umbilical vein endothelial cell, IMT, intima-media thickness, I/R, ischaemia/reperfusion, IUGR, intra-uterine growth restriction, L-NAME, NG-nitro-L-arginine methyl ester, LV, left ventricular, LVH, LV hypertrophy, MMP, matrix metalloproteinase, PlGF, placental growth factor, PKCϵ, protein kinase Cϵ, ROS, reactive oxygen species, RUPP, reduced uterine artery perfusion, SBP, systolic BP, sEng, soluble endoglin, sFlt-1, soluble fms-like tyrosine kinase-1, TGF, transforming growth factor, TIMP, tissue inhibitor of metalloproteinases, VEGF, vascular endothelial growth factor.

Previous Document:  Combined Factors Influencing the Aggregation and Deposition of nano-TiO2 in Presence of Humic Acids ...
Next Document:  Free radical biology of the cardiovascular system.